Talis Biomedical Corporation (TLIS)
NASDAQ: TLIS · IEX Real-Time Price · USD
9.07
-0.12 (-1.31%)
Apr 29, 2024, 4:00 PM EDT - Market closed
Talis Biomedical Revenue
In the year 2023, Talis Biomedical had annual revenue of $2.13M, a decrease of -55.65%. Revenue in the quarter ending December 31, 2023 was $195.00K, a -24.12% decrease year-over-year.
Revenue (ttm)
$2.13M
Revenue Growth
-55.65%
P/S Ratio
7.73
Revenue / Employee
$21,556
Employees
99
Market Cap
16.50M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2.13M | -2.68M | -55.65% |
| Dec 31, 2022 | 4.81M | -3.38M | -41.27% |
| Dec 31, 2021 | 8.19M | -2.75M | -25.10% |
| Dec 31, 2020 | 10.94M | 6.96M | 175.03% |
| Dec 31, 2019 | 3.98M | 1.59M | 66.40% |
| Dec 31, 2018 | 2.39M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Meihua International Medical Technologies Co. | 97.10M |
| VBI Vaccines | 8.68M |
| T2 Biosystems | 7.19M |
| Talphera | 651.00K |
| Orgenesis | 530.00K |
| Traws Pharma | 226.00K |
| QT Imaging Holdings | 40.36K |
TLIS News
- 5 months ago - Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash - GlobeNewsWire
- 9 months ago - Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update - GlobeNewsWire
- 9 months ago - Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023 - GlobeNewsWire
- 9 months ago - Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO) - GlobeNewsWire
- 10 months ago - Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 10 months ago - Talis Biomedical Announces 1-for-15 Reverse Stock Split - GlobeNewsWire
- 11 months ago - TALIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Talis Biomedical Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Business Wire
- 1 year ago - Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent Director - GlobeNewsWire